Eyenovia (EYEN) Stock Price, News & Analysis

Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Key Stats

• Today's Range: $1.29 to $1.37
• 50-Day Range: $1.32 to $5.28
• 52-Week Range: $1.25 to $124.80
• Volume: 107,281 shs
• Average Volume: 150,472 shs
• Market Capitalization: $1.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.00
• Consensus Rating: Hold

Eyenovia Stock Analysis - MarketRank™

Eyenovia scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Eyenovia has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Eyenovia has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eyenovia are expected to grow in the coming year, from ($41.60) to ($16.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Eyenovia is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Eyenovia is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Eyenovia has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

11.40% of the float of Eyenovia has been sold short.

Short Interest Ratio / Days to Cover

Eyenovia has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eyenovia has recently decreased by 5.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eyenovia does not currently pay a dividend.

Dividend Growth

Eyenovia does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.40% of the float of Eyenovia has been sold short.

Short Interest Ratio / Days to Cover

Eyenovia has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eyenovia has recently decreased by 5.37%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: 0.01

News Sentiment

Eyenovia has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Eyenovia this week, compared to 2 articles on an average week.

Search Interest

Only 5 people have searched for EYEN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Eyenovia to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eyenovia insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.10% of the stock of Eyenovia is held by insiders.

Percentage Held by Institutions

Only 25.84% of the stock of Eyenovia is held by institutions.

EYEN Stock Analysis - Frequently Asked Questions

How have EYEN shares performed this year?

Eyenovia's stock was trading at $11.68 on January 1st, 2025. Since then, EYEN shares have decreased by 88.6% and is now trading at $1.33.
View the best growth stocks for 2025 here.

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:EYEN) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($8.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($10.40) by $1.60. Eyenovia had a negative trailing twelve-month return on equity of 1,108.24% and a negative net margin of 114,639.41%.

When did Eyenovia's stock split?

Shares of Eyenovia reverse split on the morning of Monday, February 3rd 2025. The 1-80 reverse split was announced on Tuesday, January 28th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 31st 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

When did Eyenovia IPO?

Eyenovia (EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

Who are Eyenovia's major shareholders?

Eyenovia's top institutional shareholders include Geode Capital Management LLC (41.54%), Citadel Advisors LLC and Concourse Financial Group Securities Inc.. Insiders that own company stock include Stuart M Grant, Tsontcho Ianchulev, Michael M Rowe, Charles E Iv Mather, Ellen R Strahlman and Bren Kern.
View institutional ownership trends.

How do I buy shares of Eyenovia?

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Eyenovia own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Eyenovia investors own include Plug Power (PLUG), Advanced Micro Devices (AMD), Micron Technology (MU), OPKO Health (OPK), Pfizer (PFE), NVIDIA (NVDA) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 3/25/2025
• Next Earnings (Estimated): 3/31/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:EYEN
• CIK: 1682639
• Web: www.eyenoviabio.com
• Phone: (917) 289-1117
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $2.00
• High Stock Price Target: $2.00
• Low Stock Price Target: $2.00
• Potential Upside/Downside: +50.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($58.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-27,260,000.00
• Net Margins: -114,639.41%
• Pretax Margin: -114,639.41%
• Return on Equity: -1,108.24%
• Return on Assets: -139.36%

Debt

• Debt-to-Equity Ratio: 0.58
• Current Ratio: 0.74
• Quick Ratio: 0.55

Sales & Book Value

• Annual Sales: $31,832.00
• Price / Sales: 58.20
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $16.32 per share
• Price / Book: 0.08

Miscellaneous

• Outstanding Shares: 1,393,000
• Free Float: 1,294,000
• Market Cap: $1.85 million
• Optionable: Optionable
• Beta: 1.29